Search

OBJECTIVE: To probe into the clinical efficacy and safety of sacubitril valsartan in the treatment of heart failure induced by ischemic cardiomyopathy(ICM) and dilated cardiomyopathy (DCM). METHODS: Totally 124 patients with heart failure admitted into Jiangsu Province Hospital from Mar. 2018 to Mar. 2020 were selected and divided into ICM group (n =59) and DCM group (n = 65) according to the causes of heart failure. Both groups were given conventional anti-heart failure drugs combined with sacubitril valsartan orally for continuous 12 months. The blood pressure, N-terminal B-type natriuretic peptidogen ( NT-proBNP ), serum creatinine ( Cr ), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and serum potassium ion concentration, left ventricular ejection fraction (LVEF) and left ventricular end-diastolic diameter (LVEDD) levels before and after 6 and 12 months of treatment were observed in both groups. The 6 min walk distance (6MWT), Minnesota living with heart failure questionnaire ( mlHFQ) scores before and after 12 months of treatment were observed in both groups, and the incidences of adverse drug reactions were compared between two groups. RESULTS: The differences in NT-proBNP, Cr, ALT and AST levels, and serum potassium ion concentration between two groups after 6 and 12 months of treatment were not statistically significant (P>0. 05). Compared with before treatment, the NT-proBNP and LVEDD levels were significantly decreased and the LVEF levels were significantly increased in both groups after 6 months and 12 months of treatment, with statistically significant differeces (P<0. 05). The LVEF level was significantly higher and the LVEDD level was significantly lower in the ICM group than in the DCM group after 12 months of treatment, with statistically significant differences (P<0. 05). The 6MWT was significantly longer and the mlHFQ scores was significantly lower in both groups after 12 months of treatment, and the differences were statistically significant compared with those of before treatment (P<0. 05); while the 6MWT of the ICM group was significantly longer than that of the DCM group after 12 months of treatment, and the difference between two groups was statistically significant (P <0. 05). The incidence of adverse drug reactions of the ICM group was 5. 08% (3/59), and that of the DCM group was 6. 15% (4/65), the difference between two groups was not statistically significant (P>0. 05). CONCLUSIONS: Sacubitril valsartan can improve cardiac function and life quality in patients with heart failure induced by dilated cardiomyopathy and ischemic cardiomyopathy, and inhibit the ventricular remodeling; the improvement effect of sacubitril valsartan in patients with heart failure induced by ischemic cardiomyopathy is better than that of heart failure induced by dilated cardiomyopathy. [ABSTRACT FROM AUTHOR]